Bangkok Post - April 29, 2007
Kultida Samabuddhi
The organisation was not a "non-profit" organisation working on the protection of intellectual property and innovation as it had claimed, but in fact a proxy of the American pharmaceutical businesses, he said.
USA for Innovation on Wednesday kicked off an advertising campaign against "Thailand's Theft of American Assets".
The campaign includes a full-page advertisement in the Wall Street Journal, and highlights a recent movement by the Thai 'military regime' to steal American medical innovations, according to the organisation.
Over 35,00 letters would be delivered to President George W Bush, US administration officials and the congressional leadership urging Washington to "take retaliatory action in the form of trade or economic sanctions or the removal of military aid".
The advertisement, under the headline "Slouching Towards Burma", says Gen Surayud Chulanont is taking Thailand down Burma's path, by lining the military's pockets with pay increases of $9 million and new military spending of $1.1 billion.
"Then coup leaders hastily imposed draconian measures on foreign-owned companies like capital controls, restrictions on business advertising and stealing American assets for military benefit," the advertisement says, referring to Public Health Minister Mongkol na Songkhla's recent decision to break the patent of Aids and heart disease drugs produced by US drug firms, including Abbott Laboratories and Merck.
"In a global economy, American innovation is our comparative advantage.
We urge President Bush and the Congress to protect America's interest and the people of Thailand," it says.
The agency also ran an online action campaign on its website, www.usaforinnovation.org, where people could petition Thai ambassador to Washington Krit Garnjana-Goonchorn.
Another activist said Ken Adelman, USA for Innovation's executive director, is a senior counsellor at Edelman Public Relations Worldwide, which runs public relations campaign for several giant drug firms in the US including Abbott, Merck, and Sanofi-Aventis.
070429
BP070409
Copyright © 2007 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .